JP2013518051A - 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト - Google Patents

長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト Download PDF

Info

Publication number
JP2013518051A
JP2013518051A JP2012550140A JP2012550140A JP2013518051A JP 2013518051 A JP2013518051 A JP 2013518051A JP 2012550140 A JP2012550140 A JP 2012550140A JP 2012550140 A JP2012550140 A JP 2012550140A JP 2013518051 A JP2013518051 A JP 2013518051A
Authority
JP
Japan
Prior art keywords
intraocular pressure
bromo
hours
eye
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518051A5 (enExample
Inventor
ジョン イー ドネロ
ダニエル ダブリュー ジル
モハメッド アイ ディバス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013518051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2013518051A publication Critical patent/JP2013518051A/ja
Publication of JP2013518051A5 publication Critical patent/JP2013518051A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012550140A 2010-01-21 2011-01-21 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト Pending JP2013518051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21
US61/296,912 2010-01-21
PCT/US2011/022001 WO2011091225A2 (en) 2010-01-21 2011-01-21 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015211447A Division JP2016026206A (ja) 2010-01-21 2015-10-28 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト

Publications (2)

Publication Number Publication Date
JP2013518051A true JP2013518051A (ja) 2013-05-20
JP2013518051A5 JP2013518051A5 (enExample) 2014-03-13

Family

ID=44169074

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012550140A Pending JP2013518051A (ja) 2010-01-21 2011-01-21 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
JP2015211447A Pending JP2016026206A (ja) 2010-01-21 2015-10-28 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
JP2017086952A Expired - Fee Related JP6466504B2 (ja) 2010-01-21 2017-04-26 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015211447A Pending JP2016026206A (ja) 2010-01-21 2015-10-28 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
JP2017086952A Expired - Fee Related JP6466504B2 (ja) 2010-01-21 2017-04-26 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト

Country Status (17)

Country Link
US (1) US9889088B2 (enExample)
EP (1) EP2525793B1 (enExample)
JP (3) JP2013518051A (enExample)
KR (1) KR20120125305A (enExample)
CN (1) CN102770135A (enExample)
AU (1) AU2011207301A1 (enExample)
BR (1) BR112012018154A2 (enExample)
CA (1) CA2787573A1 (enExample)
CL (1) CL2012002038A1 (enExample)
CO (1) CO6592108A2 (enExample)
IL (1) IL221030A0 (enExample)
MX (1) MX2012008516A (enExample)
RU (1) RU2012134065A (enExample)
SG (1) SG182637A1 (enExample)
TW (1) TW201141477A (enExample)
WO (1) WO2011091225A2 (enExample)
ZA (1) ZA201205470B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2013016073A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
CN105188700A (zh) * 2013-03-14 2015-12-23 阿勒根公司 通过玻璃体内和前房内途径用于治疗眼内压和眼部疾病的α-2肾上腺素能激动剂
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
WO2019004080A1 (ja) 2017-06-27 2019-01-03 国立大学法人東京大学 融合遺伝子及び／又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
EP4236932A4 (en) * 2020-11-02 2024-10-09 Visus Therapeutics, Inc. Degradant compound in a medicament
CN118541148A (zh) * 2021-11-10 2024-08-23 视觉治疗股份有限公司 增强抗老花眼作用的碳酰胆碱制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004270A1 (en) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives
JPH09507216A (ja) * 1993-12-17 1997-07-22 ザ、プロクター、エンド、ギャンブル、カンパニー ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2603044A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Alpha-2 adrenergic agonists for the treatment of pain
CA2641501A1 (en) 2006-02-06 2007-08-16 Nicox S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507216A (ja) * 1993-12-17 1997-07-22 ザ、プロクター、エンド、ギャンブル、カンパニー ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途
WO1996004270A1 (en) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives

Also Published As

Publication number Publication date
AU2011207301A1 (en) 2012-08-09
US20110178145A1 (en) 2011-07-21
KR20120125305A (ko) 2012-11-14
ZA201205470B (en) 2013-05-29
CA2787573A1 (en) 2011-07-28
JP6466504B2 (ja) 2019-02-06
WO2011091225A2 (en) 2011-07-28
EP2525793A2 (en) 2012-11-28
CL2012002038A1 (es) 2012-11-16
CN102770135A (zh) 2012-11-07
SG182637A1 (en) 2012-08-30
WO2011091225A3 (en) 2012-05-18
BR112012018154A2 (pt) 2016-04-05
MX2012008516A (es) 2012-10-15
CO6592108A2 (es) 2013-01-02
EP2525793B1 (en) 2018-09-05
US9889088B2 (en) 2018-02-13
JP2016026206A (ja) 2016-02-12
IL221030A0 (en) 2012-09-24
TW201141477A (en) 2011-12-01
RU2012134065A (ru) 2014-02-27
JP2017125074A (ja) 2017-07-20

Similar Documents

Publication Publication Date Title
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
US20210308130A1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
RU2470635C2 (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
RS63136B1 (sr) Lekoviti sastav koji sadrži tivozanib
KR20140056280A (ko) 비마토프로스트 및 브리모니딘의 고정된 용량 조합
CA2560559C (en) Aqueous intraocular penetration-promoting eye drop
WO2023152642A1 (en) Ophthalmic compositions and methods thereof
JP2011144111A (ja) 軸性近視の予防または治療剤
CA2454544A1 (en) Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient
US20140275197A1 (en) Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
KR20150119082A (ko) 국소 안구 진통제
JP6963651B2 (ja) エピナスチン又はその塩を含有する水性組成物
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
WO2006098292A1 (ja) 眼疾患治療剤
IL322606A (en) Alpha-2-adrenergic agonists for improving vision
JP2009079041A (ja) リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151005